<i>Klebsiella pneumoniae</i> Glycoconjugate Vaccine Leads Based on Semi‐Synthetic O1 and O2ac Antigens
Klebsiella pneumoniae (KP) is a common opportunistic pathogen that emerged as a new critical threat to human health, due to its hypervirulence and widespread resistance against many antibiotics, including carbapenems. Alternative intervention strategies such as vaccines are not available. Cell-surface lipopolysaccharides (LPS) and capsular polysaccharides (CPS) are attractive targets for vaccine development. We present a method to synthesize LPS substructures, covering over 70 % of virulent KP strains that were used to characterize the antibody repertoire of infected patients. Thereby, glycoconjugate vaccine leads against the Klebsiella pneumoniae serotypes O1, O2a, O2afg and O2ac have been identified.
Authors
- Peter H. Seeberger (ORCID: https://orcid.org/0000-0003-3394-8466)
- Bettina C. Fries (ORCID: https://orcid.org/0000-0002-6847-5518)
- Julinton Sianturi (ORCID: https://orcid.org/0000-0001-7802-3403)
- Rajat Singh (ORCID: https://orcid.org/0000-0001-9996-0797)
- Tilman Lingscheid (ORCID: https://orcid.org/0000-0001-5377-3152)
- Pinkus Tober‐Lau (ORCID: https://orcid.org/0000-0002-9148-3663)
- Florian Kurth (ORCID: https://orcid.org/0000-0002-3807-473X)
- Fabienne Weber
Institutions
- California Institute of Technology (US)
- Humboldt-Universität zu Berlin (DE)
- Stony Brook School (US)
- Max Planck Institute of Colloids and Interfaces (DE)
- Stony Brook Medicine (US)
- Northport VA Medical Center (US)
- German Center for Lung Research (DE)
- Stony Brook University (US)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Angewandte Chemie International Edition
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1002/anie.202419516
- Citations
- 3
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.51
Funders
- National Institutes of Health